Prostate cancer is one disease area where the treatment environment has been improving with the increasing number of treatment options listed for health reimbursement benefits.

Recently, Pluvicto (vipivotide tetraxetan), a radioligand therapy with a new mechanism of action, has emerged and is attracting attention as a viable new standard of care.

Although the prescription is still in its early stages in Korea, it is already expanding its influence in the global market.

At a meeting with Dailypharm, SeungJu Lee, Professor of Urology; Byung-Yong Sim, Professor of Oncology; and Hyuk-Jin Yoon, Professor of Nuclear Medicine at Catholic University St.Vincent’s Hospital, expressed